Using semaglutide to manage heart disease in overweight and obese patients: expert advice

Declaration of competing interest AF has received consultancy fees during the past two years from Eli Lilly, Novo Nordisk, Novartis, and Vifor. MI has received speaker honoraria and was consultant for Astra, Boehringer, Novo Nordisk, Lilly. PS has received honoraria from Eli Lilly, Novo Nordisk, Boehringer Ingelheim, Pfizer, Roche, and Amryt Pharma (Chiesi), Theras as a member of advisory boards and payment of honoraria for lectures from Eli Lilly, Novo Nordisk, and Amryt Pharma (Chiesi). LB has received personal fees as members of advisory board from Amgen, Boehringer Ingelheim, Bruno Farmaceutici, Eli-Lilly, Novo Nordisk, Pfizer, Recordati, Regeneron and Roche and speaker honorarium from Pronokal and Rhythm Pharmaceuticals. All other authors declare no competing interests to declare that are relevant to the content of this article.